Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Investor Presentation (April 2025)
32 slides from Swedish Orphan Biovitrum Ab's investor presentation, April 2025
Slide 1: This is Sobi
This is Sobi D Investor presentation April 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Table of contents
Table of contents Slide Sobi Key facts and business model 4 Latest results – Q1 2025 and business area update 14 Sustainability at Sobi 23 Pipeline and upcoming news flow 27 IR contacts 30 Notes 31
Slide 4: Sobi: Global biopharma company developing and commercialising rare disease therapies
Sobi: Global biopharma company developing and commercialising rare disease therapies Clear strategy with proven execution: • Source: Successful BD track record building pipeline via partnerships and acquisitions • Develop: Deep clinical-stage pipeline spanning multiple rare disease areas • Commercia
Slide 5: Rare diseases are an attractive market and expected to grow faster than general pharma
Rare diseases are an attractive market and expected to grow faster than general pharma • ~7,000 rare disease have been identified with only an Sobi well positioned within rare diseases estimated 130 with marketed treatments Current Sobi areas • High medical unmet need and treatments offering signifi
Slide 6: Business model - source, develop and commercialise in the rare disease space
Business model - source, develop and commercialise in the rare disease space 2018 2019 2020 2022 2023 Acquisitions Source Licensing Develop Driving clinical development with potential new molecules and expansion of existing medicines Europe +14% 2024: Revenue: SEK 26,027 M North America + 4% Commerc
Slide 7: Strong record of successful achievements in delivering medicines to rare disease patients
Strong record of successful achievements in delivering medicines to rare disease patients around the world Selected examples from the Sobi portfolio Source Novimmune Dova Apellis CTI Pharma ITP - FDA approval 2018 pHLH - FDA approval 2018 PNH - EU approval 2021 MF – FDA approval 2022 EU approval 202
Slide 8: Next wave of catalysts to drive growth
Develop Next wave of catalysts to drive growth Asset Indication Phase 2 Phase 3 Registration C3G and IC-MPGN Pivotal VALIANT data presented at ASN Kidney Week 2024; Aspaveli/Empaveli Filed in EU February 2025 (pegcetacoplan) Post-HSCT-associated microangiography HLH / MAS in Stills disease FDA prior
Slide 9: Strong progress in pipeline in 2024
Develop Strong progress in pipeline in 2024 Haemophilia-A: Altuvoct EU approval Aspaveli/ C3G and IC-MPGN: C3G and IC-MPGN: PNH: Empaveli Positive VALIANT phase 3 data Submission to EMA* First-line approval in EU VEXAS: Vonjo IND granted by FDA ITP: Paediatric extension Doptelet submitted to FDA ITP
Slide 10: Growth driven by core business area and all regions
Commercialise Growth driven by core business area and all regions Sales (SEK B) Sales (SEK B) Haematology Immunology Specialty Care Europe North America Royalty including Beyfortus US International 26 26 22.1 18.8 22.1 15.3 15.5 18.8 14.2 14.2 15.3 15.5 9.1 9.1 2018 2019 2020 2021 2022 2023 2024 201
Slide 11: Looking ahead to 2025
Looking ahead to 2025 Anticipated major pipeline news flow 2025 outlook 2025 Aspaveli / Empaveli – Nephrology • EU regulatory decision Revenue • Japan regulatory submission Anticipated to grow by a high-single Gamifant1 – HLH / MAS • US regulatory decision digit percentage at CER • Japan regulatory
Slide 12: Sobi's near term building block of the future
Sobi’s near term building block of the future Investment in 2025 for multiple launches in 2025/26 2 3 4 Major launches Key filing Priority development projects in area of high 1. Altuvoct 1. Gamifant - HLH/MAS unmet medical need 2. Vonjo 2. Aspaveli - C3G/IC- MPGN 1. Gamifant - IDS 3. NASP - uncontr
Slide 13: Management Team
Management Team 13 sobi.com/executive committee
Slide 14: Latest results Q1 2025 and business area update
Latest results Q1 2025 and business area update
Slide 15: Positive progress in our strategic portfolio
Positive progress in our strategic portfolio Overall Portfolio grew 23% at CER (exc RSV & final ReFacto revenue) Q1 growth impacted by last ReFacto manufacturing revenue and last strong sales of Synagis in Q1 2024 Revenue Q1: SEK 6,465 M, +3% Adjusted EBITA margin Q1: 36% Portfolio grew +23% excludi
Slide 16: Solid growth trajectory in the first quarter
Solid growth trajectory in the first quarter Driven by existing and launch medicines and continued growth geographically Revenue by segment Revenue by region Q1 2025 change contrib. Q1 2025 change SEK M % % SEK M % Haematology 4,632 +13 72 Europe 2,518 +19 – Haemophilia 2,823 +3 44 North America 2,1
Slide 17: Strong momentum across the portfolio in Q1
Strong momentum across the portfolio in Q1 First quarter 2025 Haematology • Haemophilia A: Growing 29 % driven by robust Altuvoct Elocta 1 272 -5% launch Altuvoct 455 >200% Alprolix 581 -5% • Doptelet: Continued strong demand across all markets Altuviiio royalty 220 +9% with 47 % growth Other Haem r
Slide 18: Altuvoct: Strong launch success in Germany & Switzerland
Altuvoct: Strong launch success in Germany & Switzerland Continuous initial sales progress across Europe & Middle East Achieved 57% share in prophylactic factor market in Haemophilia A in Germany since launch Haemophilia A sales SEK 1,727 M +29% Q1 Altuvoct launch: • First quarter 2025 sales of SEK
Slide 19: Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026
Aspaveli: Best-in-class Phase 3 efficacy data, on track for EU nephrology launch in 2026 Aspaveli/Empaveli SEK 333 M +39% Q1 PNH • Continued growth across markets, Q1 2025 SEK 333 M, growth 39% at CER • Perseverance in markets with new competition Nephrology*: EU filing in Q1, CHMP opinion expected
Slide 20: Vonjo: Stable demand but sales impact in Q1
Vonjo: Stable demand but sales impact in Q1 Vonjo SEK 306 M -6% Q1 • Three quarters of consecutive growth followed by consolidation in Q1 • Demand volume stable quarter over quarter • Patient share remains consistent with overall share ~10% • Underlying revenue growth impacted by stocking and higher
Slide 21: Q1 2025 Revenue and profit & loss
Q1 2025 Revenue and profit & loss Q1 Q1 Full-year Total revenue (SEK M) Amounts in SEK M 2025 2024 Change 2024 Haematology Immunology Specialty Care Total revenue 6,465 6,256 3% 26,027 Adjusted Gross profit 1,2 4,968 4,735 5% 20,326 7 436 6 894 385 Adjusted Gross margin 1,2 77% 76% 78% 6 256 311 6 4
Slide 22: Sobi Outlook 2025
Sobi Outlook 2025 Key considerations for 2025 2025 outlook • Altuvoct launch progress Revenue • Continued progress with commercial portfolio Anticipated to grow by a high single- • Beyfortus royalty digit percentage at CER • Launch preparation • In US for NASP in uncontrolled gout • In Europe for As
Slide 23: Sustainability at Sobi
O) @sobl Sustainability at Sobi
Slide 24: Sustainability strategy drives business priorities
Sustainability strategy drives business priorities Commitment to patients Responsible behaviour Sobi’s climate targets • Access to treatment • Safe, fair, and healthy work approved by SBTi • Patient centricity and engagement • Inclusive, diverse workplace • Patient and product safety • Lower environ
Slide 25: Commitment to patients
Commitment to patients For more details: Sustainability performance | Sobi Access to treatment Humanitarian aid Patient centricity ~ 42,000 people treated* with • Four international patient councils to medicines from Sobi. advise on early clinical development. • 525 employees completed training in p
Slide 26: Always act responsibly
Always act responsibly For more details: Sustainability performance | Sobi Caring for employees Reduced footprint Responsible sourcing Compliance • Gender composition (%) • A 77% reduction in CO2- intensity between 2016 95% Mean score 64 95% and 2023 (from 0,3 to 0,07 between completed Code of of So
Slide 27: Pipeline and upcoming news flow
Pipeline and upcoming news flow
Slide 28: Progress to be continued in 2025
Progress to be continued in 2025 Anticipated major pipeline news flow Aspaveli NASP Gamifant CHMP opinion Finalising FDA FDA decision PMDA submission submission 2025 H1 2025 H2 Gamifant – HLH / MAS in Still’s disease Gamifant – HLH / MAS in Still’s disease o US regulatory decision o Japan regulatory
Slide 29: Solid pipeline progress in Q1 2025
Solid pipeline progress in Q1 2025 C3G and IC-MPGN Aspaveli/Empaveli EMA application successfully submitted HLH/MAS in Still’s disease Gamifant FDA priority review granted Interferon-γ driven sepsis (IDS) First patient enrolled in PoC study1 Synovitis SHINE Altuvoct First patient enrolled in Phase 4
Slide 30: Sobi IR contacts
Sobi IR contacts Investors page on sobi.com
Slide 31: Notes on Haemophilia and RSV business
Notes on Haemophilia and RSV business Haemophilia • Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio in the US. • Sobi has final developmen
Slide 32: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2023 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com
Swedish Orphan Biovitrum AB (Sobi) — Investor Presentation (April 2025) on 6ix